Free Trial

Cigna Considers Humana Acquisition – What It Means for the Stocks

Health care and medical services concept with flat line AR interface.medical techonlogy concept,smart doctor hand working with modern laptop computer in modern office with virtual icon diagram - stock image

Key Points

  • Speculation is circulating about a potential Cigna Group Acquisition of Humana to form one of the largest health insurers in the country.
  • Antitrust and regulatory concerns are major hurdles to a deal.
  • Medicare Advantage may be the ticking time bomb that sabotages the prospects of a deal.
  • MarketBeat previews the top five stocks to own by June 1st.

There has been speculation of a massive merger in the medical sector between two massive health insurers. Specifically, the rumor is The Cigna Group NYSE: CI is interested in acquiring Humana Inc. NYSE: HUM. The conjecture caused both stocks to react, as Cigna stock fell 10% as the rumored surfaced on Oct. 18, 2024, and Humana stock remained relatively flat. Based on the reactions, the market doesn't see this as a favorable merger, and for good reason.

While there are many potential synergies in a merger, assuming it passes the regulatory antitrust sniff test (which is a big "if"), there is also a major sticking point that sinks any possibility of it coming to fruition called Medicare Advantage (MA).

Medicare: What It Is and How It Works

Medicare is a federal-sponsored health insurance plan available to Americans aged 65 or older. Its premiums are taken directly out of monthly Social Security benefits payments. Medicare is comprised of four parts:

  • Part A covers inpatient hospital bills, home or skilled nursing, and hospice.
  • Part B covers medical bills, including doctor visits, procedures and services, outpatient care and preventative care, as well as medical supplies and lab services.
  • Part D covers prescription drugs.

Medicare follows a physician fee schedule that is released by the Centers for Medicare and Medicaid Services (CMS) every year, detailing how much the standard reimbursements are for every covered medical procedure under Medicare Part B. The fee schedule applies to fee-for-service, which reimburses on an itemized basis comprised of 80% from Medicare and 20% as a co-pay from the Medicare patient.

For example, a Medicare-participating doctor may bill $300 for a consult but only be eligible for a $100 reimbursement based on the Medicare fee schedule, while $80 is paid by Medicare and $20 is paid by the patient. If a patient has prescriptions to fill, then Medicare will pay 80%, and the patient is responsible for the 20%. The 20% patient responsibility can add up fast, which can be a major financial burden for seniors living on a fixed income. The health insurers, notably managed care organizations, applied their tactics to develop an all-inclusive type of health insurance funded mostly by Medicare payments.

Medicare Advantage Sounds Great on Paper  

The fourth part of Medicare is Part C, which is known as Medicare Advantage. This health insurance covers Parts A, B, and D in one plan. The premiums are taken directly from Social Security as traditional Medical would. A co-premium may apply for some options, which may include additional coverage. Medicare Advantage plans are known to offer additional benefits like health and wellness programs, gym memberships, transportation to and from the doctor's office, and preventative care. Initially, it seemed like an incredible bargain as seniors no longer had to pay additional monies out of pocket for expensive prescriptions or hospital bills.

Everyone was happy, as patients got full coverage with no more than 20% co-insurance payments. Medicare Advantage Plan providers like Humana and UnitedHealth Group Inc. NYSE: UNH made big profits. However, doctors, facilities, hospitals and medical providers were regularly getting stiffed, denied or underpaid from capitation.  

Medicare Advantage Plan Costs Surge

Humana Today

Humana Inc. stock logo
HUMHUM 90-day performance
Humana
$274.11 -0.85 (-0.31%)
As of 05/11/2026 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range
$163.11
$315.35
Dividend Yield
1.29%
P/E Ratio
29.32
Price Target
$247.61

The unraveling occurred during the fall of 2023 when hospital/inpatient utilization rates surged seemingly out of the blue. This means that more seniors end up in hospitals using expensive resources. Humana shocked investors when they released their fourth quarter of 2023 earnings report, citing a surge in MA costs from inpatient utilization. Humana slashed their 2025 and 2024 full-year EPS guidance by 50% to 75%. For the full year 2025, adjusted EPS was cut to $16.00 versus $29.14 consensus estimates. Adjusted EPS for 2025 was slashed from $6.00 to $10.00 from the previous forecast of $37.00.

Like a contagion, other health insurers were also feeling the pain of rising MA plan member costs as medical benefit ratios (MBR) grew, squeezing margins. CVS Health Co. NYSE: CVS has been dealing with rising MA costs, pumping up its MBRs as it helped tank its adjusted operating income by 39.1% YoY. CVS Health recently replaced its CEO and is rumored to be contemplating splitting off with its Aetna health insurance subsidiary.

Cigna Saw the Writing on the Wall

Cigna Group Today

Cigna Group stock logo
CICI 90-day performance
Cigna Group
$288.86 +0.80 (+0.28%)
As of 05/11/2026 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range
$239.51
$338.89
Dividend Yield
2.16%
P/E Ratio
12.24
Price Target
$338.35

Amidst the turmoil with health insurers, Cigna saw the writing on the wall and swiftly exited the MA business. They sold their Medicare business, which included Medicare Advantage, Medicare Part D, and the Cigna Supplemental Benefits businesses, to Healthcare Services Group Inc. NASDAQ: HCSG for $3.3 billion.

Cigna had the foresight and took prudent action. An acquisition of Humana would be the equivalent of playing hot potatoes with a ticking time bomb. A merger with Humana would make Cigna one of the largest health insurers in the country, but it would come with a lot of cost synergies.  

However, the reality is that MA makes up the majority of Humana's income, comprising over 85% of its premium income. Cigna can't overlook that fact, as it would be re-entering a business that it was prudent enough to divest before it became a major issue.

Should You Invest $1,000 in Humana Right Now?

Before you consider Humana, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.

While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Jea Yu
About The Author

Jea Yu

Contributing Author

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Cigna Group (CI)
4.9293 of 5 stars
$288.860.3%2.16%12.24Moderate Buy$338.35
Humana (HUM)
3.621 of 5 stars
$274.11-0.3%1.29%29.32Hold$247.61
UnitedHealth Group (UNH)
4.181 of 5 stars
$384.401.2%2.30%29.03Moderate Buy$378.88
CVS Health (CVS)
4.5714 of 5 stars
$92.221.8%2.88%40.63Moderate Buy$96.12
Healthcare Services Group (HCSG)
3.9114 of 5 stars
$22.35-3.1%N/A23.28Moderate Buy$24.00
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines